Commencement of share buyback programme

Summary by AI BETAClose X

Fevertree Drinks PLC has commenced a share buyback programme with a maximum consideration of £30 million, which will run until December 31, 2026, with the intention to cancel all repurchased shares to reduce share capital. The company has entered into a non-discretionary agreement with Investec Bank plc to execute these purchases, adhering to regulatory requirements and existing shareholder authorities.

Disclaimer*

Fevertree Drinks PLC
02 February 2026
 

2 February 2026

Fevertree Drinks plc

("Fever-Tree" or the "Company")

 

Commencement of share buyback programme

Further to the announcement on 29 January 2026, Fever-Tree today announces the commencement of a share buyback programme regarding the purchase of ordinary shares in the Company with a nominal value of 0.25 pence each (the "Shares") up to a maximum consideration of £30 million (the "Programme").

Fever-Tree has entered into a non-discretionary agreement with Investec Bank plc ("Investec") to purchase Shares on its behalf and to make trading decisions independently of the Company. The Programme will commence today, 2 February 2026, and end no later than 31 December 2026. The sole purpose of the Programme is to reduce the share capital of Fever-Tree. As such, the Company intends to cancel any Shares purchased.

Investec will purchase the Shares as principal and simultaneously be deemed to execute sales to the Company of any Shares so purchased in accordance with the terms of their engagement.

Any purchase of Shares under the Programme will be executed in accordance with certain pre-set parameters and in accordance with the Company's existing general authority to repurchase Shares granted by its shareholders at the annual general meeting held on 5 June 2025 (which permits the Company to purchase no more than 12,453,469 Shares, with authority remaining for 6,122,332 Shares following the buyback programme executed in 2025, as may be updated subject to shareholder approval at the 2026 annual general meeting), the Market Abuse Regulation (596/2014) as it forms part of domestic law by virtue of section 3 of the European Union (Withdrawal) Act 2018 (as amended) and UKLR 9.6.2. The Company may repurchase up to 25% of the average daily trading volume in the Shares in the 20 trading days preceding the date on which a buy-back of Shares is carried out.

 

For more information please contact: 

 

Investor queries

Steve Nightingale, Investor Relations Director I steve.nightingale@fever-tree.com I +44 (0)7951 849 564

Media queries

Oliver Winters, Director of Communications I oliver.winters@fever-tree.com I +44 (0)770 332 9024

 

Nominated Advisor and Broker - Investec Bank plc

David Flin I +44 (0)20 7597 5970

Corporate Broker - Jefferies International Limited

Ed Matthews I +44 (0)20 7029 8000

Financial PR advisers - FGS Global

Faeth Birch +44 (0)7768 943 171; Anjali Unnikrishnan +44 (0) 7826 534 233

 

 

Notes to the Editors:

Fever-Tree is the world's leading supplier of premium carbonated mixers by retail sales value, with distribution to over 95 countries worldwide. Based in the UK, the brand was launched in 2005 to provide high quality mixers which could cater to the growing demand for premium spirits, in particular gin, but also increasingly for vodka, rum and whisky. The Company now sells a range of carbonated mixers and soft drinks to hotels, restaurants, bars and cafes ("On Trade") as well as a broad range of retail outlets ("Off Trade").

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings